News
Feed
Events
Feed
News
+ Events
Feed

AFFiRiS AG

  • Land Österreich

Aktuelle News

22 Dezember 2021

10:00 Corporate

AFFiRiS AG

Corporate

AFFiRiS und Frontier Biotechnologies geben Lizenzvereinbarung für AFFITOPE(R)AT04, eine aktive Immuntherapie gegen PCSK9 zur Behandlung von Hypercholesterinämie, für die Region Greater China bekannt

27 Juli 2021

14:00 Corporate

AFFiRiS AG

Corporate

AC Immune erwirbt AFFiRiS’ Anti-Alpha-Synuclein Spezifische Aktive Immuntherapie (SAIT) – Programme gegen neurodegenerative Erkrankungen

27 Mai 2021

11:00 Corporate EN

AFFiRiS AG

Corporate
EN

AFFiRiS: Positive phase 1 results with immunotherapies targeting PCSK9 to treat hypercholesterolemia published by the European Journal of Clinical Pharmacology

27 April 2021

09:00 Corporate EN

AFFiRiS AG

Corporate
EN

AFFiRiS AG: Positive preclinical in vivo results with AFFiRiS’ antibody mAB C6-17 to treat Huntington’s disease to be presented at the 16th Annual Huntington’s Disease Therapeutics Conference

11 September 2020

14:00 Corporate EN

AFFiRiS AG

Corporate
EN

AFFiRiS announces late-breaking presentation of clinical PD01 data in Parkinson’s disease patients at the MDS Virtual Congress

10 September 2020

10:00 Corporate EN

AFFiRiS AG

Corporate
EN

AFFiRiS announces publication in Movement Disorders Journal of positive clinical results of a Phase 1 trial in early Multiple System Atrophy

18 Juni 2020

09:05 Corporate

AFFiRiS AG

Corporate

The Lancet Neurology veröffentlicht positive Ergebnisse der Phase 1-Studie von AFFiRiS mit PD01A bei Parkinson-Patienten

3 Juni 2020

09:30 Corporate EN

AFFiRiS AG

Corporate
EN

Neurobiology of Disease publishes encouraging preclinical results of AFFiRiS’ antibody mAB C6-17 to treat Huntington’s disease

9 April 2020

09:30 Corporate EN

AFFiRiS AG

Corporate
EN

World Parkinson’s Day: AFFiRiS developing PD01 to treat Parkinson’s disease, a major unmet medical need

3 März 2020

10:30 Corporate EN

AFFiRiS AG

Corporate
EN

AFFiRiS granted new patent in China for treating Parkinson’s disease

27 Januar 2020

10:00 Corporate EN

AFFiRiS AG

Corporate
EN

AFFiRiS Announces FDA Response to its pre-IND Submission for Phase 2 trial with AFFITOPE PD01 in Early Parkinson’s Disease Patients

10 Januar 2020

10:00 Corporate EN

AFFiRiS AG

Corporate
EN

AFFiRiS announces Phase 2 study in Parkinson’s and new focus on neurodegenerative diseases

Anstehende Events

Keine Events gefunden